Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Juno Therapeutics Inc.

Division of Celgene Corp.
www.junotherapeutics.com

Latest From Juno Therapeutics Inc.

GSK's Hal Barron On R&D Progress At Two-Year Mark

Chief scientific officer at GSK, Hal Barron, talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.

C-Suite Speaks Research and Development Strategies

Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration

GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.

Deals Business Strategies

Culture Change At GSK: 'We’re Doing What We Said We’d Do'

Chief scientific offficer Hal Barron talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.

 

Human Capital ImmunoOncology

BIO 2019 Notebook: M&A Soars, Lartruvo Lookback, BIO Vs. ASCO

News and views from day four of the BIO International Convention: emerging company M&A deals nearly double in 2018; former FDA official Amy McKee said "everything worked right" with accelerated approval and removal of Lilly's Lartruvo; and the ASCO effect on the 3-6 June BIO meeting.

Drug Review Review Pathway
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register